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Introduction {#s1}
============

In the healthy organism, bone remodeling is performed by the balanced activity of bone-forming osteoblasts and bone-resorbing osteoclasts, assuring the constant renewal of bone tissue and maintenance of adequate bone stability [@pone.0114360-Harada1], [@pone.0114360-Teitelbaum1]. In osteoporosis, the most prevalent bone disease worldwide, a relative increase of bone resorption over bone formation occurs, thereby resulting in bone loss and a subsequent increase in fracture risk [@pone.0114360-Zaidi1]. As excessive osteoclastogenesis is detrimental not only in osteoporosis, but also tumor-induced osteolysis and Paget\'s disease of bone [@pone.0114360-Roodman1], [@pone.0114360-Goltzman1], the molecular understanding of the processes regulating osteoclast formation and function is of paramount clinical importance.

Osteoclasts represent highly specialized, multinuclear giant cells, which are formed by the fusion of hematopoietic precursor cells from the monocyte/macrophages lineage. The process of osteoclast formation (osteoclastogenesis) depends on two essential cytokines, macrophage colony-stimulating factor (M-CSF) [@pone.0114360-Kodama1], [@pone.0114360-Dai1] and receptor activator of nuclear factor kappa-B ligand (RANKL) [@pone.0114360-Lacey1], [@pone.0114360-Yasuda1], which are produced by bone marrow cells and osteoblasts, respectively. While M-CSF is required for the early differentiation of monocytes and macrophages, RANKL is essential for the subsequent cellular fusion to yield mature and functional osteoclasts. This is best demonstrated by mice lacking RANKL which display osteopetrosis, a condition characterized by the absence of functional osteoclasts and resulting in a marked increase in bone mass with consecutive displacement of bone marrow [@pone.0114360-Kong1], [@pone.0114360-Kim1]. Through binding to the receptor activator of nuclear factor κB (RANK), expressed on osteoclasts and their precursors, RANKL activates two key transcription factors, nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) and cytoplasmic calcineurin/nuclear factor of activated t cells (NFATC1), which have been demonstrated to be of crucial importance for osteoclastogenesis [@pone.0114360-Matsuo1], [@pone.0114360-Takayanagi1] Once fully differentiated, osteoclasts express *Acp5* (Tartrate-resistant acid phosphatase) and *Calcr* (Calcitonin receptor) and attach to the bone matrix, which is subsequently resorbed by the secretion of hydrochloric acid and matrix-degrading peptidases [@pone.0114360-Boyle1].

While many systemic and local factors, including endocrine organs, the central nervous system, and mechanical load bearing, have been identified as pivotal regulators of bone turnover [@pone.0114360-Rodan1], [@pone.0114360-Turner1], recent research has unraveled an unanticipated role of cell adhesion molecules in the regulation of bone cell differentiation and function. For example, vascular cellular adhesion molecule 1, which is expressed on myeloma cells and interacts with integrins mediating osteoclast attachment to bone surface, was shown to tether osteoclast progenitors to accelerate their maturation, thus facilitating tumor-induced osteolysis [@pone.0114360-Michigami1], [@pone.0114360-Pearse1]. Furthermore, it could be demonstrated that the intercellular adhesion molecule-1 provides a high affinity adhesion between osteoblast and osteoclast precursors, thereby enhancing the binding of Rank to membrane-bound Rankl on osteoblasts [@pone.0114360-Tanaka1]. Another group of cell-to-cell adhesion molecules that has raised great scientific and clinical interest in recent years are carcinoembryonic antigen-related cell adhesion molecules (CEACAMs), representing a subdivision of the immunoglobulin-related glycoproteins. Apart from functioning as receptors for host-specific bacteria and viruses, CEACAMs have been shown to regulate tissue architecture, cell-to-cell recognition, tumor proliferation, neovascularization and metastasis [@pone.0114360-Kuespert1]. However, despite the extensive characterization of CEACAMs in pathologic conditions such as inflammation and cancer, their role in bone remodeling remained unclear to date.

In the present study, we found *Ceacam1* and *Ceacam10* to be expressed in bone marrow and tissue, including osteoblasts and osteoclast precursors. While no alterations in bone remodeling were detected in *Ceacam10*-deficient mice, an osteoporotic bone phenotype due to increased osteoclastogenesis was observed in mice lacking *Ceacam1*. *Ex vivo* assays demonstrated an increased osteoclast formation in bone marrow cultures derived from *Ceacam1*-deficient mice, which was accompanied by an elevated expression of *Nfatc1*, the master transcription factor governing osteoclastogenesis. Taken together, these findings not only provide *in vivo* and *in vitro* evidence for a role of CEACAM1 in the regulation of bone remodeling, they also raise the possibility that pharmacologic targeting of CEACAM1 may be an alternative approach to treat skeletal disorders caused by excessive bone resorption.

Materials and Methods {#s2}
=====================

1. Animals {#s2a}
----------

*Ceacam1*- and *Ceacam10*-deficient animals were generated and genotyped as described previously [@pone.0114360-Bickert1], [@pone.0114360-Ludewig1], [@pone.0114360-Finkenzeller1]. All animal experiments were approved by the local animal care committee.

2. Skeletal analysis {#s2b}
--------------------

All mice received dual calcein injections for the determination of the bone formation rate at 9 and 7 days before sacrifice. The lumbar vertebrae were dehydrated and embedded non-decalcified into methyl methacrylate for sectioning. 4 µm-thin sections were stained with toluidine blue or von Kossa/van Gieson procedure as described [@pone.0114360-Albers1]. Static and cellular histomorphometry was carried out using the OsteoMeasure system (Osteometrics, Decatur, USA) following the guidelines of the American Society of Bone and Mineral Research. Dynamic histomorphometry for the determination of the bone formation rate was performed on non-stained 12 µm-sections. The cortical thickness and the mean diameter of femora were quantified by µCT scanning using a µCT 40 (Scanco Medical).

3. Primary osteoblasts {#s2c}
----------------------

Primary osteoblasts were isolated from bone marrow cells derived from 12 to 18-week-old mice as described [@pone.0114360-Albers2]. At 80% confluency, cells were differentiated by adding β-glycerophosphate and ascorbic acid. For staining with alizarin red, cells were fixed with 90% ethanol, washed twice with water and incubated with 40 mM alizarin red staining solution (pH 4.2). After washing, the stained cultures were incubated with 10% acetic acid to quantify matrix mineralization. After removing the cellular remnants by centrifugation, the supernatant was neutralized with ammonium hydroxide, and absorption was determined at 405 nm.

4. Primary osteoclasts {#s2d}
----------------------

For the assessment of osteoclastogenesis, the bone marrow from 12 to 18-week-old mice was flushed out of the femora as described previously [@pone.0114360-Albers2]. At day 2 of differentiation, M-CSF (Peprotech) was added, followed by RANKL (Peprotech) at day 4.

For TRAP-activity staining, cells were washed with PBS and then fixed in cold methanol. After two washing steps with distilled water, the fixed cells were dried before the TRAP-specific substrate naphthol AS-MX phosphate (Sigma-Aldrich) was added. For the quantification of osteoclast formation, the number of TRAP-positive, multinucleated (\>3 nuclei/cell) cells per well was determined.

5. RAW264.7 cell line {#s2e}
---------------------

RAW264.7 cells were obtained from ATCC (Wesel, Germany) and cultured in DMEM containing 10% fetal calf serum. For induction of osteoclastogenesis cells were cultured with RANKL for 5 days.

6. Expression analysis {#s2f}
----------------------

Total RNA was isolated from indicated tissues, whole and marrow-flushed bones, or primary bone cells using the RNeasy Minikit (QIAGEN). Subsequently, DNase digestion was performed according to the manufacturer\'s instructions. Concentration and quality of extracted RNA was measured using an ND-1000 system (NanoDrop Technology). For cDNA synthesis, 0,5--1 µg of RNA was reverse transcribed using cAMV First-Strand Synthesis Kit (Invitrogen) according to the manufacturer\'s instructions. For semi-quantitative RT-PCR analysis, the following primers were used to amplify fragments of *Ceacam1^a^* (5′-TCAGCACATCTCCACAAAGG-3′ and 5′-CTCTCTGCCGCTGTATGCTT-3′), *Ceacam1/2* (5′-AGCGTCAGGAGGAGCAACTCAA-3′ and 5′-AGAAGAAGGGGCTGAAGTTGGC-3′), *Ceacam2* (5′-GCTATGAAAAGCAGGGCAGA-3′ and 5′-TGAAATTGTCCAGTCAGGACC-3′), *Ceacam9* (5′-CTTAACCTGCTGGAATGCACCCGCCG-3′ and 5′-CAGCTTCTGTTACCGCGGTGCTGTCT-3′), *Ceacam10* (5′-GCTAGATCAAAACTTTGAAATTACTCC-3′ and 5′-ACAGGCATTAGGGTATGATCG-3′), *Ceacam11* (5′-CACAGGAGTTAAACCACTCAAGAA-3′ and 5′-AAACCTGCAGGAGAATATTGTCA-3′), *Ceacam12* (5′-AAGGAGGTAAACTGCTCAAGAT-3′ and 5′-AGTTGAGAAGTAGGATGCTTTC-3′), *Ceacam13* (5′-GGAGCTGCACCGTTCAAGT-3′ and 5′-TGCGTCTTTCTTCTTGACATTG-3′), *Ceacam14* (5′-CCTGGTTCACAGGAGCTAGAGT-3′ and 5′-GGCATCTGAAAGACCCACAA-3′), *Ceacam15* (5′-CCTCTAAAGAAATGCGCTTCTC-3′ and 5′-GACACGCAGGTGAGAATTGA-3′), *Ceacam16* (5′-TCCTGGTGGCCAGTTACATT-3′ and 5′-GCTGCTACAGACGAGACGAA-3′), *Ceacam17* (5′AAACGGCCGATAGACAACGA-3′ and 5′-GAACGGGTCACTATGGAAGG-3′), *Ceacam18* (5′-TGAAGTGGACACTAGCAACG-3′ and 5′-TGCTTAGGAAGGAGCCGTTA-3′), *Ceacam19* (5′CACATCGAGATGATCCCAGA-3′ and 5′-TCCCAATGATGATGGCTACC-3′), *Ceacam20* A1-B1-domain (5′-CAAGCTCACCCTCACAGTCA-3′ and 5′-AAGTTCACGGTGTTGCCTTC-3′), *Ceacam20* B2-cytopl. domain 5 (5′-GATCTGCCTCTGTCCTGGTC-3′ and 5′-TGGGGTGATCTTGCAGTAAA-3′), *Psg17* (5′-GGTACAAAGGGGTGGCAA-3′ and 5′- CAAGCTTGTTAAACACAACTGCT-3′), *Psg30* (5′-CTGCACAAATAACCATTGAATTAGA-3′ and 5′-CTTGACTTGCAAAGGGTGATAA-3′), *Psg31* (5′-CATCCCTTTCTACTTGCTACCAA-3′ and 5′-GCTCAGATTTCTCCTCTGCAATT-3′) and *β--actin* (5′-ATG GAT GAC GAT ATC GCT-3′ and 5′-ATGAGGTAGTCTGTCAGGT-3′) according to the study by Zebauser et al. [@pone.0114360-Zebhauser1]. Due to a considerable homology *Ceacam1a* and *Ceacam2* were specifically amplified in addition to *Ceacam1/2* in order to detect expression of *Ceacam1*. Quantitative RT-PCR expression analysis was performed using StepOnePlus predesigned TaqMan gene expression assays (Applied Biosystems). *β--actin* or *Gapdh* expression was used as an internal control, as indicated. For western blotting CEACAM1 protein was detected using the polyclonal rabbit anti-CEACAM1 antiserum "P1" after transfer of proteins from an SDS-page onto a PVDF membrane [@pone.0114360-Horst1].

7. Serum analysis {#s2g}
-----------------

Serum concentrations of bone-specific collagen degradation products (Crosslaps) and OPG were quantified using antibody-based detection kits (\#AC-06F1, Immunodiagnostic Systems; \#MOP00, R&D Systems; \#MTR00, R&D Systems). Mice were fasted for 4 h prior to blood sampling.

8. Immunofluorescence {#s2h}
---------------------

For visualization of the actin cytoskeleton, cells were fixed in Formafix (Pathomed, Germany), followed by permeabilization with ice-cold acetone and rinses in phosphate buffered saline. Subsequently, cells were stained with fluorescein-labelled phalloidin and 4′,6-diamidin-2-phenylindol (DAPI; both Molecular Probes, Germany) at room temperature in the dark (1∶300 in phosphate buffered saline). After washes in phosphate buffered saline, slides were mounted with Vectashield mounting media (Vector Labs, United Kingdom). Pictures were taken on a Leica DM5000B fluorescent microscope (Leica, Germany).

9. Statistical analysis {#s2i}
-----------------------

All data were analyzed by two-tailed Student\'s t test using Excel software. All data are reported as mean ± SD. p\<0.05 was considered statistically significant.

Results {#s3}
=======

To elucidate a potential role of CEACAMs in bone remodeling, we monitored the expression of all genes of the CEACAM family in whole bone, bone marrow and marrow-flushed bone. While the expression of most members was not detectable by semi-quantitative PCR, we exclusively found *Ceacam1* and *Ceacam10* expression in bone and bone marrow ([S1 Figure](#pone.0114360.s001){ref-type="supplementary-material"}). Comparing the expression in various tissues, *Ceacam1* and *Ceacam10* were expressed at comparable levels in bone samples ([Fig. 1A](#pone-0114360-g001){ref-type="fig"}). Interestingly, while the expression of *Ceacam1* was highest in liver and femur, *Ceacam10* was expressed at much higher levels in all bone specimens compared to non-skeletal tissues ([Fig. 1A](#pone-0114360-g001){ref-type="fig"}). To further characterize the expression of *Ceacam1* and *Ceacam10* in the course of osteoblast and osteoclast formation, we differentiated bone marrow cells into osteoblasts and osteoclasts and performed quantitative RT-PCR. Here we found that the expression of both *Ceacam1* and *Ceacam10* increased during the early stages of osteoblast differentiation, and decreased towards terminal osteoblast differentiation ([Fig. 1B](#pone-0114360-g001){ref-type="fig"}). In addition, although *Ceacam1* and *Ceacam10* were both expressed at high levels in undifferentiated bone marrow cultures, their expression markedly decreased during the course of osteoclastogenesis ([Fig. 1C](#pone-0114360-g001){ref-type="fig"}). This observation was confirmed in experiments using the macrophage cell line RAW264.7 where we found *Ceacam1* to be differentially expressed during the course of osteoclastogenesis on mRNA ([Fig. 1D](#pone-0114360-g001){ref-type="fig"}) and protein level ([Fig. 1E](#pone-0114360-g001){ref-type="fig"}).

![Expression of *Ceacam1* and *Ceacam10* in various tissues and differentiated bone cells.\
(A, B) qRT-PCR of *Ceacam1* and *Ceacam10* in various tissues. nd  =  not detectable. (C) qRT-PCR of the same genes during osteoblast (Obl) differentiation at the indicated days (d) of differentiation, using *Bglap* expression (OSTEOCALCIN) as a control. (D) qRT-PCR of *Ceacam1* and *Ceacam10* during osteoclast (Ocl) differentiation at the indicated days (d) of differentiation, using *Calcr* expression (CALCITONIN RECEPTOR) as a control. (E) qRT-PCR of *Ceacam1* and *Ceacam10* in undifferentiated (undiff.) and differentiated (diff.) RAW cells, using *Acp5* expression (TRAP) as a control. (F) Western blot showing CEACAM1 expression in cell lysates from undifferentiated and differentiated RAW cells. Arrows indicate size of the nearest marker. All bars represent mean + SD (n≥3 independent experiments). Asterics indicate statistically significant differences compared to day 0 in the case of osteoblasts or day 1 in the case of osteoclasts, respectively (p\<0.05).](pone.0114360.g001){#pone-0114360-g001}

As this observation pointed towards a specific role of CEACAM1 and CEACAM10 in the regulation of bone remodeling, we next applied non-decalcified bone histology in mice lacking the respective genes. Von Kossa staining of spine sections from 6-month-old mice demonstrated a reduced bone mass in *Ceacam1*-deficient mice compared to WT controls, whereas no alteration could be detected in mice lacking CEACAM10 ([Fig. 2A](#pone-0114360-g002){ref-type="fig"}). These findings were confirmed by static histomorphometry, which demonstrated *Ceacam1*-deficient mice exhibit decreased trabecular bone volume accompanied by a reduction in trabecular number and an increase in trabecular separation ([Fig. 2B](#pone-0114360-g002){ref-type="fig"}). In contrast, none of these parameters were altered in mice lacking CEACAM10. In order to analyze whether the observed phenotype is also detectable in younger mice, we additionally performed static histomorphometry of 3-month-old mice. Spine sections of *Ceacam1*-deficient mice were characterized by a significantly reduced trabecular bone mass accompanied by reduced trabecular numbers ([S2 Figure](#pone.0114360.s002){ref-type="supplementary-material"}), similar to what was observed in 6-month-old animals. In addition, 3-month-old mutant animals displayed a reduced trabecular thickness and increased trabecular separation ([S2 Figure](#pone.0114360.s002){ref-type="supplementary-material"}). To address the question whether the lack of *Ceacam1* not only affects skeletal architecture in vertebrae, but also long bones, we finally performed histomorphometry of non-decalcified tibia sections and µCT-scanning of femora derived from *Ceacam1*-deficient mice. While we found a decreased trabecular bone volume accompanied by a decrease in trabecular numbers in the tibiae of mutant animals ([Fig. 3A](#pone-0114360-g003){ref-type="fig"}), cortical thickness and mean diameter were unaltered in the femora of *Ceacam1*-deficient mice ([Fig. 3B](#pone-0114360-g003){ref-type="fig"}).

![Decreased trabecular bone mass in 6-month-old mice lacking *Ceacam1*.\
(A) Von Kossa staining of non-decalcified spine sections from controls (*Ceacam1^+/+^*, *Ceacam10^+/+^*) and *Ceacam1*- or *Ceacam10*-deficient mice (*Ceacam1^-/-^*, *Ceacam10^-/-^*). Histomorphometric quantification of the trabecular bone volume (BV/TV, bone volume per tissue volume), trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and trabecular separation (Tb.Sp.). All bars represent mean ± SD (n = 5 mice per group). Asterisks indicate statistically significant differences (p\<0.05).](pone.0114360.g002){#pone-0114360-g002}

![Analysis of long bones derived from 6-month-old mice lacking *Ceacam1*.\
(A) Von Kossa staining of non-decalcified tibia sections from controls (*Ceacam1^+/+^*) and *Ceacam1*-deficient mice (*Ceacam1^-/-^*) and histomorphometric quantification of the trabecular bone volume (BV/TV) and trabecular number (Tb.N.) below. (B) µCT scanning of femora derived from the same mice. Mean femoral diameter and cortical thickness (C.Th.) are indicated below. All bars represent mean ± SD (n = 5 mice per group). Asterisks indicate statistically significant differences (p\<0.05).](pone.0114360.g003){#pone-0114360-g003}

These findings suggested an important role of CEACAM1 in the regulation of trabecular bone remodeling, while CEACAM10 was found to have no overt effect. Therefore, we focused our further analyses on CEACAM1 and performed a full histomorphometric characterization of the spine sections derived from 6-month-old *Ceacam1*-deficient mice. Cellular histomorphometry using toluidine-blue stained spine sections revealed no alteration in the number of osteoblasts or osteoblast surface, indicating normal osteoblastogenesis in *Ceacam1*-deficient mice ([Fig. 4A](#pone-0114360-g004){ref-type="fig"}). Likewise, dynamic histomorphometry following dual calcein labeling demonstrated a normal bone formation rate, ruling out an impaired osteoblast function as the underlying cause of the observed phenotype. In contrast, *Ceacam1*-deficient mice were found to display an increased number of osteoclasts and osteoclast surface, suggesting increased bone resorption ([Fig. 4B](#pone-0114360-g004){ref-type="fig"}). Although an absolute increase in collagen degradation products was undetectable ([Fig. 4C](#pone-0114360-g004){ref-type="fig"}), normalization of serum crosslaps to the reduced bone mass revealed an elevated net bone resorption in mice lacking CEACAM1 (data not shown).

![Increased osteoclastogenesis in mice lacking *Ceacam1*.\
(A) Histomorphometric quantification of the osteoblast number per bone perimeter (ObN/BPm), osteoblast surface per bone surface (ObS/BS) and the bone formation rate per bone surface (BFR/BS). (B) Quantification of the osteoclast number per bone perimeter (OcN/BPm), osteoclast surface per bone surface (OcS/BS). (C) Quantification of serum crosslaps. All bars represent mean ± SD (n = 5 mice per group). Asterisks indicate statistically significant differences (p\<0.05).](pone.0114360.g004){#pone-0114360-g004}

In order to analyze, whether the observed increase in osteoclastogenesis could be explained by gross alterations in OPG levels, we measured this cytokine in the serum of *Ceacam1*-deficient mice and controls by ELISA. While no changes were detectable in 3-month-old *Ceacam1*-deficient mice, we measured an increased concentration of OPG in 6-month-old mice, pointing towards an age-dependent compensatory regulation *in vivo* in the light of enhanced osteoclastogenesis. This assumption was confirmed *in vitro*, were we detected normal expression of *Tnfsf11* and *Tnfrsf11b*, encoding RANKL and OPG, in primary osteoblasts at day 10 of differentiation ([S3 Figure](#pone.0114360.s003){ref-type="supplementary-material"}).

Investigating the possibility of cell-autonomous defects in these mice, we next differentiated WT and *Ceacam1*-deficient bone marrow cells into osteoblasts and osteoclasts *ex vivo*. Von Kossa staining at day 10 of differentiation revealed a normal formation of mineralized nodules in *Ceacam1*-deficient osteoblast cultures ([Fig. 5A](#pone-0114360-g005){ref-type="fig"}). Likewise, the assessment of alizarin red staining demonstrated regular extracellular matrix mineralization in osteoblasts derived from *Ceacam1*-deficient mice. In addition, normal levels of intracellular alkaline phosphatase activity were measured, ruling out a functional osteoblast defect caused by *Ceacam1*-deficiency ([Fig. 5B](#pone-0114360-g005){ref-type="fig"}). In contrast, TRAP-activity staining of *Ceacam1-*deficient bone marrow cells cultured in the presence of M-CSF and RANKL displayed a marked increase in osteoclastogenesis at day 7 of differentiation ([Fig. 5C](#pone-0114360-g005){ref-type="fig"}), while no alteration in the number of nuclei per osteoclast could be detected by immunofluorescence ([Fig. 5D](#pone-0114360-g005){ref-type="fig"}). To understand this effect on the molecular level, we finally screened for differentially expressed genes essential for osteoclast differentiation and function. On day 0 of differentiation, no significant differences could be measured among the tested genes ([Fig. 5E](#pone-0114360-g005){ref-type="fig"}). On day 3 of differentiation, only a tendency towards a reduced expression of *Tm7sf4*, encoding the fusion protein DC-STAMP, could be detected in *Ceacam1*-deficient cultures, whereas the expression of the late osteoclast marker gene *Calcr* was still undetectable in mutant and control cells. In contrast, on day 4 of differentiation we observed a trend towards enhanced expression of *Acp5* and significantly increased expression of *Nfatc1* ([Fig. 5E](#pone-0114360-g005){ref-type="fig"}). However, while the increased expression of *Acp5* was only temporarily detectable, we found *Nfatc1* to be overexpressed in *Ceacam1*-deficient osteoclasts again at day 7, pointing towards a crucial role of this key transcription factor in mediating the effects of CEACAM1 on osteoclastogenesis.

![Accelerated osteoclast formation in bone marrow cells lacking *Ceacam1*.\
(A) Alizarin red and von Kossa staining of mineralized matrix and nodules, respectively, in osteoblast cultures at day 10 of differentiation. The quantification of Alizarin red staining extracellular matrix mineralization is indicated on the right. (B) Quantification of intracellular alkaline phosphatase activity in bone marrow-derived osteoblast cultures at day 10 of differentiation. (C) TRAP activity staining of terminally differentiated osteoclasts. The quantification of TRAP-positive, multinuclear osteoclasts is given on the right. (D) Immunofluorescence using DAPI (nucleus) and Phalloidin (actin) staining of osteoclast cultures at day 7 of differentiation. The quantification of the number of nuclei per osteoclast (Nuclei/Oc) is indicated on the right. (E) qRT-PCR expression analysis of the indicated genes (*Acp5*, Tartrate-resistant acid phosphatase; *Tmf7sf4*, DC-STAMP, dendrocyte-expressed seven transmembrane protein; *NF-κB*, nuclear factor kappa-light-chain-enhancer of activated B-cells; *Nfat1c*, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, *Tnfrsf11a*, receptor activator of nuclear factor κB, Rank; *c-Fos*, FBJ osteosarcoma oncogene; and *Calcr*, Calcitonin receptor) at day 0, 3, 4 and 7 of osteoclast differentiation. All bars represent mean ± SD (n = 3 cultures per group). Asterisks indicate statistically significant differences (p\<0.05).](pone.0114360.g005){#pone-0114360-g005}

Discussion {#s4}
==========

The molecular understanding of bone remodeling represents an ongoing clinical challenge, as therapeutic options for skeletal disorders such as osteoporosis and tumor-induced osteolysis caused by excessive osteoclast function remain limited. While the biological actions of CEACAMs have been studied extensively in the context of pathological conditions including inflammation, stroke and cancer [@pone.0114360-Kuespert1], [@pone.0114360-Ludewig1] a potential role in the regulation of bone turnover has not been sufficiently addressed to date. This is indeed surprising, given the growing body of evidence establishing a link between skeletal integrity and immune or cancer cells not only in basic, but also clinical research. For example, rheumatoid arthritis, a chronic autoimmune disease characterized by joint destruction, is considered to be driven by the secretion of pro-inflammatory cytokines including TNFα and IL-17 from lymphocytes, resulting in excessive activation of osteoclasts [@pone.0114360-Brennan1], [@pone.0114360-Kotake1]. Likewise, expression of IL-1β and inhibitors of Wnt signaling, such as DKK-1, in tumor cells have been reported to be involved in malignant osteolysis through both an activation of osteoclastogenesis and an inhibition of bone formation [@pone.0114360-Tian1], [@pone.0114360-Lust1]. Based on their broad array of biological effects in the immune system and tumorigenesis, it was thus important to analyze the role of CEACAMs in the regulation of bone turnover.

Monitoring the expression of all genes encoding the members of the CEACAM family, we could exclusively detect the expression of *Ceacam1* and *Ceacam10* in bone tissue. Although this observation does not necessarily rule out a potential role of other Ceacams in bone remodeling, they pointed towards a specific function of CEACAM1 and CEACAM10 in regulating bone cell function. This notion was further supported by the high cDNA levels of the two encoding genes in bone tissue compared to other organs. Based on the specific expression dynamics of both *Ceacam1* and *Ceacam10* during osteoblast and osteoclast differentiation, we went on to analyze the bone phenotype of the respective animal models. While *Ceacam10*-deficiency was not associated with any alterations in structural bone parameters, static histomorphometry demonstrated a decreased trabecular bone volume in 3- and 6-month old *Ceacam1*-deficient mice. This was indeed an interesting finding, as *Ceacam1*-deficient mice, under basal conditions, have been reported to display no gross phenotypical abnormalities [@pone.0114360-Kuespert1]. As mentioned above, while previous studies have primarily focused on the pathophysiologic functions of CEACAM1 in various *in vivo* and *in vitro* disease models, this observation pointed towards a physiologic role of CEACAM1 in the regulation of bone cell activity.

Although *Ceacam1* was differentially expressed during osteoblastogenesis, the cellular and dynamic histomorphometry failed to detect defective osteoblastogenesis or osteoblast function. Surprisingly, increased osteoclast parameters were found in trabecular bone, indicating accelerated osteoclastogenesis in *Ceacam1*-deficient mice. To further characterize this effect at the cellular level, we differentiated bone marrow cells into osteoblasts and osteoclasts. In line with our *in vivo* observations, primary osteoblasts derived from *Ceacam1*-deficient mice displayed normal matrix mineralization and alkaline phosphatase activity *in vitro*. In contrast, although no alteration in the numbers of nuclei per osteoclasts could be detected, *Ceacam1*-deficient bone marrow cells demonstrated an increased osteoclastogenesis when cultured with M-CSF and RANKL. Therefore, it is now possible to conclude that CEACAM1 functions as a negative regulator of osteoclastogenesis *in vivo* and *in vitro*. The fact that we could detect increased levels of serum OPG in 6-month old animals is interesting, however does not explain the observed bone phenotype and increased osteoclastogenesis associated with the lack of CEACAM1. This is supported by the finding that 3-month-old mutant animals displayed a low bone mass phenotype despite normal OPG levels. Furthermore, as we failed to detect differences in the expression of *Tnfsf11* and *Tnfrsf11b* in primary osteoblasts derived from *Ceacam1*-deficient mice, this particular phenomenon is most likely explained by an age-dependent counter regulatory mechanism rather than an intrinsic osteoblast defect.

On the molecular level, we could detect differential expression of *Ceacam1* not only in bone marrow derived osteoclast progenitors, but also in the pure macrophage cell line RAW264.7, providing a potential explanation for the increased osteoclast formation in *Ceacam1*-deficient mice. Since the formation of mature osteoclasts primarily depends on RANKL-induced activation of key transcription factors and the subsequent expression of several osteoclast marker genes, we monitored the expression of *NF-κβ*, *Nfatc1*, *Acp5*, *Tmf7sf4*, *Tnfrsf11a*, *c-Fos*, and *Calcr* during osteoclastogenesis in bone marrow cells derived from WT and *Ceacam1*-deficient mice. While indicators of mature osteoclasts, including *Calcr* and *Acp5*, were found to be expressed at similar or only temporarily elevated levels compared to WT controls, respectively, increased expression of *Nfatc1* in *Ceacam1*-deficient cells was found at day 4 and 7 of osteoclast differentiation. As this coincided with the induction of monocyte/macrophage fusion into mature osteoclasts by the addition of RANKL to these cultures, it appears tempting to speculate that CEACAM1 may modulate osteoclastogenesis through the regulation of NFATC1, the master transcription factor required for osteoclast differentiation. Although a previous study reported a stimulatory effect of a short splice variant of CEACAM1 on the expression of *Nfatc1* in CD4^+^ T cells [@pone.0114360-Chen1], further research is necessary to elucidate the influence of CEACAM1 on the regulation of this transcription factor specifically in osteoclasts and myeloid-derived cells`.` This is of particular importance, as the liver-specific inactivation of *Ceacam1*, characterized by hyperinsulinemia and glucose intolerance, results in decreased osteoclastogenesis [@pone.0114360-Huang1]. Thus, it appears that the impact of global *Ceacam1* deletion, including cells of the osteoclast lineage, is dominant over the effects of hepatic *Ceacam1* expression on bone metabolism.

Taken together, our study reports a novel function of CEACAM1 in bone remodeling. Using *in vivo* and *in vitro* assays, we demonstrate that deficiency of CEACAM1 is associated with a reduced bone mass due to increased osteoclastogenesis, at least in mice. Given its previously reported function in regulating tumor cell differentiation and the immune system, future studies investigating the role of CEACAM1 in pathologic bone conditions, such as tumor-induced osteolysis and inflammation-induced bone loss, will be of crucial importance.

Supporting Information {#s5}
======================

###### 

**Expression of** ***Ceacam*** **genes in bone tissue and differentiated bone cells.** RT-PCR of the indicated genes in the spine (S), femur (F), flushed femur (FF) and bone marrow (BM) using the same primers as described previously (26).

(TIF)

###### 

Click here for additional data file.

###### 

**Decreased trabecular bone mass in 3-month-old mice lacking** ***Ceacam1*** **.** Von Kossa staining of non-decalcified spine sections from controls (*Ceacam1^+/+^*) and *Ceacam1*-deficient mice (*Ceacam1^-/-^*). Histomorphometric quantification of the trabecular bone volume (BV/TV, bone volume per tissue volume), trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and trabecular separation (Tb.Sp.). All bars represent mean ± SD (n = 5 mice per group). Asterisks indicate statistically significant differences (p\<0.05).

(TIF)

###### 

Click here for additional data file.

###### 

**OPG in** ***Ceacam1*** **-deficient mice.** (A) Serum concentrations of OPG in 3- and 6-month old *Ceacam1*-deficient mice. (B) qRT-PCR of *Tnfsf11* and *Tnfrsf11b* encoding RANKL and OPG, respectively, in primary osteoblasts at day 10 of differentiation. All bars represent mean ± SD (n = 5 mice and n = 3 cultures per group, respectively). Asterisks indicate statistically significant differences (p\<0.05).

(TIF)

###### 

Click here for additional data file.
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